MXPA04003866A - Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. - Google Patents

Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.

Info

Publication number
MXPA04003866A
MXPA04003866A MXPA04003866A MXPA04003866A MXPA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A MX PA04003866 A MXPA04003866 A MX PA04003866A
Authority
MX
Mexico
Prior art keywords
agonist
estrogen
treating unstable
overactive bladder
muscarinic agent
Prior art date
Application number
MXPA04003866A
Other languages
English (en)
Spanish (es)
Inventor
Versi Ebrahim
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MXPA04003866A publication Critical patent/MXPA04003866A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA04003866A 2001-11-09 2002-11-07 Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. MXPA04003866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34450701P 2001-11-09 2001-11-09
PCT/SE2002/002041 WO2003039524A1 (en) 2001-11-09 2002-11-07 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder

Publications (1)

Publication Number Publication Date
MXPA04003866A true MXPA04003866A (es) 2004-07-08

Family

ID=23350815

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04003866A MXPA04003866A (es) 2001-11-09 2002-11-07 Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
MXPA04004364A MXPA04004364A (es) 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA04004364A MXPA04004364A (es) 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.

Country Status (6)

Country Link
US (2) US20030118633A1 (enExample)
EP (2) EP1441707A1 (enExample)
JP (2) JP2005512995A (enExample)
CA (2) CA2466336A1 (enExample)
MX (2) MXPA04003866A (enExample)
WO (2) WO2003039524A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053292A1 (en) 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
AU2003287248A1 (en) * 2002-11-12 2004-06-03 Pharmacia And Upjohn Company Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, an estrogen and an antimuscarinic
JP2006515026A (ja) 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP2400300A1 (en) * 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
AU2006270221B2 (en) 2005-07-15 2012-01-19 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
EP2289486A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
EP2029128B1 (en) 2006-05-22 2015-08-05 Hormos Medical Ltd. Method of treatment of chronic nonbacterial prostatitis with selective estrogen receptor modulators or aromatase inhibitors
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
CN101678388B (zh) 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
WO2008086369A1 (en) 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
CA2688314C (en) 2007-05-25 2013-12-03 Micell Technologies, Inc. Polymer films for medical device coating
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20110152227A1 (en) * 2008-04-09 2011-06-23 Concert Pharmaceuticals Inc. Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof
MX2010011485A (es) 2008-04-17 2011-03-01 Micell Technologies Inc Stents que contienen capas bioadsorbibles.
GR1006406B (el) * 2008-05-06 2009-05-26 Specifar Abee ���������� ������� ��� ������������� ��������� Μικροδισκια παρατεταμενης αποδεσμευσης της τρυγικης τολτεροδινης
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc MEDICAL ACTIVE COMPOSITION DEVICE
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
ES2713523T3 (es) * 2012-07-18 2019-05-22 Georges Debled Composición farmacéutica de mesterolona para deficiencias de dihidrotestosterona en la mujer
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
RU2713888C2 (ru) * 2013-10-10 2020-02-10 Терапьютиксмд, Инк. Фармацевтические составы и способы на основе эстрадиола для интравагинального введения
WO2018093369A1 (en) * 2016-11-17 2018-05-24 Goren Ofer A Treatment of sexual dysfunction and for improved sexual quality of life
US20240424001A1 (en) * 2021-09-10 2024-12-26 Statera Pharma Inc. Local delivery of growth and repair promoting compounds for treating, reducing and/or preventing stress urinary incontinence and fecal incontinence

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262115A (en) * 1882-08-01 Moeeis pollak
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
GEP20043354B (en) * 1998-08-27 2004-04-13 Pharmacia & Upjohn Ab Therapeutic Formulation for Administering Tolterodine with Controlled Release
PL352250A1 (en) * 1999-06-11 2003-08-11 Watson Pharmaceuticals Administration of non-oral androgenic steroids to women
NZ527012A (en) * 2001-03-28 2005-03-24 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD

Also Published As

Publication number Publication date
US20030118633A1 (en) 2003-06-26
MXPA04004364A (es) 2004-08-11
WO2003039553B1 (en) 2004-07-08
CA2466336A1 (en) 2003-05-15
EP1441707A1 (en) 2004-08-04
WO2003039524A1 (en) 2003-05-15
EP1443939A1 (en) 2004-08-11
JP2005512995A (ja) 2005-05-12
WO2003039553A1 (en) 2003-05-15
US20030130244A1 (en) 2003-07-10
JP2005514345A (ja) 2005-05-19
CA2464707A1 (en) 2003-05-09

Similar Documents

Publication Publication Date Title
MXPA04003866A (es) Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20043354B (en) Therapeutic Formulation for Administering Tolterodine with Controlled Release
CA2376916A1 (en) Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
EP1764092A3 (en) Selecting compounds for treatment of Alzheimer's disease
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
AU2003240113B2 (en) Formulation of nefopam and its use in the treatment of pain
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel
WO2003039464A3 (en) Antimuscarinic aerosol
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
WO2003015690B1 (en) Method for treating primary insomnia
AP1896A (en) The method of treating cancer
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
WO2001068076A8 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
SE0102887D0 (sv) New formulation
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
MY133438A (en) Morpholinobenzamide salts
ZA200505026B (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal